Cargando…

Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

Despite the significant advances in the treatment of multiple myeloma (MM), this disease is still considered incurable because of relapse and chemotherapy resistance, underscoring the need to seek novel therapies with different mechanisms. Anlotinib, a novel multi-targeted tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Yang, Shan, Huizhuang, Liu, Meng, Liu, Jia, Zhang, Zilu, Xu, Xiaoguang, Liu, Yue, Xu, Hanzhang, Lei, Hu, Yu, Miao, Zhang, Xingming, Liu, Wanting, Bu, Zhilei, Fang, Zhixiao, Ji, Yanjie, Yan, Hua, Gu, Weiying, Wu, Yingli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046985/ https://www.ncbi.nlm.nih.gov/pubmed/33854043 http://dx.doi.org/10.1038/s41419-021-03685-w

Ejemplares similares

IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma
por: Liu, Meng, et al.
Publicado: (2022)

YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma
por: Shan, Huizhuang, et al.
Publicado: (2020)

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance
por: Yue, Yanhua, et al.
Publicado: (2022)

JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKKβ
por: Zhang, Zilu, et al.
Publicado: (2022)

Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy
por: Tong, Jia, et al.
Publicado: (2020)

Targeting deubiquitinating enzymes in cancer stem cells
por: Lei, Hu, et al.
Publicado: (2017)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia
por: Shan, Huizhuang, et al.
Publicado: (2018)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‑2 papain-like protease: Parthenolide covalently inhibits papain-like protease
por: Zou, Zhihui, et al.
Publicado: (2022)

Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report
por: Zhang, Aixia, et al.
Publicado: (2019)

Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
por: Yao, Ruosi, et al.
Publicado: (2022)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

MYC inhibitors in multiple myeloma
por: Martínez-Martín, Sandra, et al.
Publicado: (2021)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Case Report: An Adolescent Soft Tissue Sarcoma With YWHAE-NUTM2B Fusion Is Effectively Treated With Combined Therapy of Epirubicin and Anlotinib
por: He, Jiajia, et al.
Publicado: (2022)

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
por: Dai, Shuang, et al.
Publicado: (2022)

Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer
por: Yuan, Meng, et al.
Publicado: (2022)

The Value of Anlotinib in the Treatment of Intractable Brain Edema: Two Case Reports
por: Yang, Song, et al.
Publicado: (2021)

HN1 contributes to migration, invasion, and tumorigenesis of breast cancer by enhancing MYC activity
por: Zhang, Chen, et al.
Publicado: (2017)

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2015)

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

Anaplastic multiple myeloma with MYC rearrangement
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022)

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2018)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
por: Xiao, Xinhua, et al.
Publicado: (2023)

Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells
por: Zhu, Zhongling, et al.
Publicado: (2023)

Oncogene addiction to c-MYC in myeloma cells
por: Holien, Toril, et al.
Publicado: (2012)

YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells
por: Wang, Yingying, et al.
Publicado: (2018)

Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature
por: Liu, Lei, et al.
Publicado: (2020)

Sinomenine derivative YL064: a novel STAT3 inhibitor with promising anti-myeloma activity
por: Wang, Yingying, et al.
Publicado: (2018)

Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review
por: Cheng, Ke, et al.
Publicado: (2022)

Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe
por: Deng, Zhaoming, et al.
Publicado: (2021)

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
por: Zhu, Zhongling, et al.
Publicado: (2021)

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature
por: Zhang, Yishi, et al.
Publicado: (2023)

P818: DNP73 PROMOTES DRUG RESISTANCE AND IMMUNE EVASION IN MULTIPLE MYELOMA BY MODULATING MYC/CD47 AXIS
por: Liu, Lanting, et al.
Publicado: (2023)

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
por: Xu, Huanhuan, et al.
Publicado: (2021)

TMPRSS2 Serves as a Prognostic Biomarker and Correlated With Immune Infiltrates in Breast Invasive Cancer and Lung Adenocarcinoma
por: Xiao, Xinhua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_je2ioueq98nhuohoji8hq0s529